Abstract: The present invention relates to the treatment of AML. The inventors previously discovered a new epigenetic biomarker in a cohort of CN-AML patients; this consists in a strong enrichment in the H3K27me3 histone mark located on a 70 Kb part of the major histone cluster 1 (HIST1) that separates patients into two distinguishable groups defined as H3K27me3HIST1low and H3K27me3HIST1high. Patients harboring the H3K27me3 HIST1 epigenetic mark had a better event free survival. This first observation suggests that H3K27me3HIST1high patients may develop a less aggressive disease. Molecular characterisation of H3K27me3HIST1high patients showed that the linker histone H1d, but not the other histone H1 subtypes, was down-regulated in the H3K27me3 HIST1high group of patients. H1d knockdown primed ATRA differentiation, as assessed on CD11b/CD11c markers, morphological and gene expression analyses.

Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from acute myeloid leukemia (AML) comprising i) determining in a sample obtained from the patient the expression level of NKp46 ii) comparing the expression level determined at step i) with its predetermined reference value and iii) providing a good prognosis when the expression level determined at step i) is higher than its predetermined reference value, or providing a bad prognosis when the expression level determined at step i) is lower than its predetermined reference value.

Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from acute myeloid leukemia (AML) comprising i) determining the frequency of JAM-C expressing LSCs in a sample obtained from the patient ii) comparing the frequency determined at step i) with its predetermined reference value and iii) providing a good prognosis when the frequency determined at step i) is lower than its predetermined reference value, or 10 providing a bad prognosis when the frequency determined at step i) is higher than its predetermined reference value.

Abstract: The present invention relates to an in vitro method for predicting the survival time of a subject suffering from acute myeloid leukemia (AML) comprising determining, in a biological sample from the subject, the epigenetic profile of the H3K27.

Abstract: The invention relates to a circuit configuration for the recognition of a plasma which is supplied with energy by means of an ac current of preset frequency. This ac current is detected by way of a suitable sensor and feeds to a highpass filter. This highpass filter permits those frequencies to pass through which lie above the preset frequency. The output signal of the highpass filter is rectified through a rectifier, freed of its residual ripple through a lowpass filter, and supplied to an evaluation device.